Theophylline Tablet, Extended Release
Product Images NDC 0480-3310

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Theophylline (NDC 0480-3310). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

New (Image 1)

Chemical structure of the active ingredient Theophylline, showing its molecular framework including nitrogen and oxygen atoms in a bicyclic structure with methyl groups attached.*

FDA Label Image

100 (Image 2)

Theophylline Extended-Release Tablets 300 mg label from Teva Pharmaceuticals, Inc. The label states the product contains theophylline anhydrous 300 mg per extended-release tablet. Packaging is for 100 uncoated tablets. Includes storage instructions, manufacturing details from Watson Pharma Private Limited in India, and a barcode with a serialization coding area.*

FDA Label Image

100 (Image 3)

Label for Theophylline Extended-Release Tablets 450 mg by Teva Pharmaceuticals, Inc. Contains 100 tablets in an uncoated, extended-release oral tablet form. Manufactured in India by Watson Pharma Private Limited. Includes storage instructions and barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.